MedTrace Logo

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

NCT05788835 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2023-03-29

No results posted yet for this study

Summary

This is a randomized controlled trial to determine the efficacy and safety of DEB-TACE versus DEB-TACE sequential HAIC for unresectable BCLC stage C HCC

Conditions

Interventions

PROCEDURE

DEB-TACE and HAIC

Drug-eluting bead transarterial chemoembolization sequential Hepatic Artery Chemotherapy Infusion

PROCEDURE

DEB-TACE

Drug-eluting bead transarterial chemoembolization

Sponsors & Collaborators

  • Xuhua Duan

    lead OTHER

Principal Investigators

  • Xuhua Xuhua, Ph.D. · The First Affiliated Hospital of Zhengzhou University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-07
Primary Completion
2024-06-07
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05788835 on ClinicalTrials.gov